GlaxoSmithKline faces a 1,500-strong UK class action suit early next year over its anti-depressant Seroxat, The Business newspaper said on Sunday.
http://class-action-questions.com/archives/2005/12/11/uk-suit-against-seroxat-paxil-coming-next-spring
It quoted Mark Harvey, a partner at Cardiff solicitor Hugh James, as saying he would launch the suit next spring.
Harvey was not available to comment on Sunday.
A spokesman for GlaxoSmithKline told Reuters: “We do not accept the allegations in the potential class action and will address the issues raised if litigation is pursued.”
The 1,500 litigants will claim they were not warned that the drug, prescribed for depression, could lead to addiction, the newspaper said.
They will also allege it caused aggression and in some cases suicidal thoughts, the paper said. The drug is known as Paxil in the United States.
GlaxoSmithKline Plc in August slammed a study from scientists in Norway suggesting Paxil was linked to an increased suicide risk in adults, arguing that the research was flawed and misleading.
Experts at the European Medicines Agency earlier this year reaffirmed the positive benefit-risk for Paxil in the treatment of adult anxiety and depression.
http://class-action-questions.com/archives/2005/12/11/uk-suit-against-seroxat-paxil-coming-next-spring
http://class-action-questions.com/archives/2005/12/11/uk-suit-against-seroxat-paxil-coming-next-spring
It quoted Mark Harvey, a partner at Cardiff solicitor Hugh James, as saying he would launch the suit next spring.
Harvey was not available to comment on Sunday.
A spokesman for GlaxoSmithKline told Reuters: “We do not accept the allegations in the potential class action and will address the issues raised if litigation is pursued.”
The 1,500 litigants will claim they were not warned that the drug, prescribed for depression, could lead to addiction, the newspaper said.
They will also allege it caused aggression and in some cases suicidal thoughts, the paper said. The drug is known as Paxil in the United States.
GlaxoSmithKline Plc in August slammed a study from scientists in Norway suggesting Paxil was linked to an increased suicide risk in adults, arguing that the research was flawed and misleading.
Experts at the European Medicines Agency earlier this year reaffirmed the positive benefit-risk for Paxil in the treatment of adult anxiety and depression.
http://class-action-questions.com/archives/2005/12/11/uk-suit-against-seroxat-paxil-coming-next-spring
No comments:
Post a Comment
Note: only a member of this blog may post a comment.